Regimen | No. of patients (%), n = 18 |
FOLFIRI + bevacizumab | 5 (27.7) |
IRIS + bevacizumab | 4 (22.2) |
CAPIRI + bevacizumab | 4 (22.2) |
CPT-11 + cetuximab | 4 (22.2) |
FOLFIRI + panitumumab | 1 (5.55) |